The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
Loading...
Embargo End Date
ICR Authors
Authors
Wilding, CP
Elms, ML
Judson, I
Tan, A-C
Jones, RL
Huang, PH
Elms, ML
Judson, I
Tan, A-C
Jones, RL
Huang, PH
Document Type
Journal Article
Date
2019-10-30
Date Accepted
Abstract
Introduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes including proliferation, migration, and apoptosis. As such, targeting these proteins with small molecule tyrosine kinase inhibitors (TKI) has led to significant advances in the treatment of a number of cancer types.Areas covered: Soft tissue sarcomas (STS) are a heterogeneous and challenging group of rare cancers to treat, but the approval of the TKI pazopanib for the treatment of advanced STS demonstrates that this class of drugs may have broad utility against a range of different sarcoma histological subtypes. Since the approval of pazopanib, a number of other TKIs have entered clinical trials to evaluate whether their activity in STS matches the promising results seen in other solid tumors. In this article, we review the emerging role of TKIs in the evolving landscape of sarcoma treatment.Expert opinion: As our biological understanding of response and resistance of STS to TKIs advances, we anticipate that patient management will move away from a 'one size fits all' paradigm toward personalized, multi-line, and patient-specific treatment regimens where patients are treated according to the underlying biology and genetics of their specific disease.
Citation
Expert review of anticancer therapy, 2019, 19 (11), pp. 971 - 991
Source Title
Publisher
TAYLOR & FRANCIS LTD
ISSN
1473-7140
eISSN
1744-8328
Collections
Research Team
Sarcoma Clinical Trials
Molecular and Systems Oncology
Molecular and Systems Oncology